Simran Singh is currently the CEO of Guardant Health AMEA, a precision oncology company that is a pioneer in comprehensive genomic profiling (liquid biopsies). The company has a vast portfolio of diagnostic tests across the continuum of cancer, from late-stage cancer to recurrence monitoring to early cancer detection. Guardant Health AMEA has a presence across 41 countries in Asia, Middle East and Africa. Prior to Guardant Health, Simran was the Vice President of the Global Medical Devices & Diagnostics division and Head of Strategic Planning Asia for IQVIA, a global CRO where he was instrumental in driving IQVIA’s growth strategy for Asia Pacific and accelerating revenue growth.